In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer

Yi Pang Lee, Che Wei Wang, Wan Chun Liao, Chiung Ru Yang, Chi Tai Yeh, Chung Hung Tsai, Chi Chiang Yang, Yew Min Tzeng

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Aim: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). Materials and Methods: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and 1H- nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. Results: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p

Original languageEnglish
Pages (from-to)2735-2746
Number of pages12
JournalAnticancer Research
Volume32
Issue number7
Publication statusPublished - Jul 2012

Fingerprint

Colorectal Neoplasms
HT29 Cells
Poly(ADP-ribose) Polymerases
Electrospray Ionization Mass Spectrometry
In Vitro Techniques
destruxin B
Tumor Burden
Heterografts
Caspase 3
Colonic Neoplasms
Cell Survival
Magnetic Resonance Spectroscopy
High Pressure Liquid Chromatography
Growth

Keywords

  • 5-FU
  • Colorectal cancer
  • Destruxin B
  • HT-29 cells
  • Xenograft model

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lee, Y. P., Wang, C. W., Liao, W. C., Yang, C. R., Yeh, C. T., Tsai, C. H., ... Tzeng, Y. M. (2012). In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. Anticancer Research, 32(7), 2735-2746.

In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. / Lee, Yi Pang; Wang, Che Wei; Liao, Wan Chun; Yang, Chiung Ru; Yeh, Chi Tai; Tsai, Chung Hung; Yang, Chi Chiang; Tzeng, Yew Min.

In: Anticancer Research, Vol. 32, No. 7, 07.2012, p. 2735-2746.

Research output: Contribution to journalArticle

Lee, YP, Wang, CW, Liao, WC, Yang, CR, Yeh, CT, Tsai, CH, Yang, CC & Tzeng, YM 2012, 'In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer', Anticancer Research, vol. 32, no. 7, pp. 2735-2746.
Lee YP, Wang CW, Liao WC, Yang CR, Yeh CT, Tsai CH et al. In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. Anticancer Research. 2012 Jul;32(7):2735-2746.
Lee, Yi Pang ; Wang, Che Wei ; Liao, Wan Chun ; Yang, Chiung Ru ; Yeh, Chi Tai ; Tsai, Chung Hung ; Yang, Chi Chiang ; Tzeng, Yew Min. / In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer. In: Anticancer Research. 2012 ; Vol. 32, No. 7. pp. 2735-2746.
@article{01936c2b3f7245d18732da21aadb0706,
title = "In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer",
abstract = "Aim: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). Materials and Methods: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and 1H- nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. Results: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p",
keywords = "5-FU, Colorectal cancer, Destruxin B, HT-29 cells, Xenograft model",
author = "Lee, {Yi Pang} and Wang, {Che Wei} and Liao, {Wan Chun} and Yang, {Chiung Ru} and Yeh, {Chi Tai} and Tsai, {Chung Hung} and Yang, {Chi Chiang} and Tzeng, {Yew Min}",
year = "2012",
month = "7",
language = "English",
volume = "32",
pages = "2735--2746",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - In vitro and in vivo anticancer effects of destruxin B on human colorectal cancer

AU - Lee, Yi Pang

AU - Wang, Che Wei

AU - Liao, Wan Chun

AU - Yang, Chiung Ru

AU - Yeh, Chi Tai

AU - Tsai, Chung Hung

AU - Yang, Chi Chiang

AU - Tzeng, Yew Min

PY - 2012/7

Y1 - 2012/7

N2 - Aim: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). Materials and Methods: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and 1H- nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. Results: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p

AB - Aim: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). Materials and Methods: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and 1H- nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. Results: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p

KW - 5-FU

KW - Colorectal cancer

KW - Destruxin B

KW - HT-29 cells

KW - Xenograft model

UR - http://www.scopus.com/inward/record.url?scp=84865677132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865677132&partnerID=8YFLogxK

M3 - Article

C2 - 22753733

AN - SCOPUS:84865677132

VL - 32

SP - 2735

EP - 2746

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -